The following is a summary of some recent studies on COVID-19. They include research that warrants further study to confirm the findings and that has not yet been substantiated by peer review.
Neurological risk not high after COVID-19 vaccines COVID-19 vaccination did not increase risk for rare neurological conditions in more than 8 million people who received at least one dose of vaccine from AstraZeneca, Pfizer/BioNTech, Moderna or Johnson & Johnson Was found According to the researchers.
Their study also included 735,870 non-vaccinated individuals who tested positive for the coronavirus, as well as older data on an additional 14.3 million people from the general population for a baseline estimate of rates of neurological conditions before the pandemic. The researchers looked for four neurological disorders linked to the immune system. Three of them — Bell’s palsy (facial weakness), encephalomyelitis (inflammation of the brain and spinal cord), and Guillain-Barré syndrome (a nerve condition) — were no more common in those receiving the vaccine than in the general population, the researchers said. told in The BMJ on Wednesday https://www.bmj.com/content/376/bmj-2021-068373. The fourth – transverse myelitis (inflammation of the spinal cord) – occurs too rarely to be analyzed (less than 5 cases in 8.3 million vaccinated people). However, researchers did see increased rates of Bell’s palsy, encephalomyelitis, and Guillain-Barré syndrome in COVID-19 survivors. The researchers said more research is needed to look at the long-term adverse events of vaccination and SARS-CoV-2 infection, and to study the effects of vaccines on different age groups. But it appears that COVID-19 vaccines are a “highly unlikely cause” for most neurological problems, he concluded.
An international study has found that the risk of depression, anxiety is linked to COVID-19 severity. People who have been in bed with COVID-19 for seven days or more are at increased risk of anxiety and depression.
Researchers analyzed data from Denmark, Estonia, Iceland, Norway, Sweden and the UK between March 2020 and August 2021, covering more than 247,000 people, including 9,979 who had been diagnosed with COVID-19. Those who had COVID and had been bedridden for at least a week had a 61% higher risk for depression symptoms and a 43% higher risk for anxiety, compared to those who remained in bed for at least 16 months after their diagnosis. who were never infected. In contrast, patients who had COVID-19 but had never been to bedtime actually had significantly lower rates of depression than those who had never contracted the virus, the researchers found. “This group may experience relief and return to a somewhat normal life after recovering from a relatively benign infection, who have not yet been diagnosed with COVID-19, perhaps still fearful of infection. and is therefore still limiting social interaction,” Dr. Anna Valdimarsdottir of the University of Iceland, whose team reported the findings in The Lancet Public Health https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(22)00042-1/fulltext. He said the results should alert physicians to the potential for long-term mental health symptoms in their patients who had severe severe illness from the virus.
A small study suggests that the Pfizer/BioNTech vaccine is safe after heart attack.
The inflammatory condition, called myocarditis, is a common complication of COVID and other viral infections and a rare side effect associated with some COVID-19 vaccines, mainly in young men. But among 55 patients who recovered from myocarditis within the past five years and who subsequently received a COVID-19 mRNA vaccine, none had a repeat myocarditis, researchers reported Friday at the European heart meeting ESC Acute Cardiovascular Care 2022. of https://www.escardio.org/Congresses-&-Events/Acute-Cardiovascular-Care. Of the 55 subjects, 43 had received both doses of the vaccine and 12 had received only the first dose. Almost everyone had received the Pfizer/BioNTech vaccine, the researchers said, so the findings may not apply to other shots. Nevertheless, the results “provide reassuring data that may encourage patients with a history of myocarditis to be vaccinated against SARS-CoV-2,” said study author Dr. Iyad Abu Saleh, Hospice Civiles de Lyon, France, said in a statement.
Click for Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)